Dr. Peter Gilbert is a biostatistician with many years of experience in the design and analysis of randomized clinical trials for preventive vaccines against HIV, malaria, dengue, and other pathogens; as well as for MTCT prevention and antiretroviral therapies. Through his work as co-PI of the statistical data management center (SDMC) for the HIV Vaccine Trials Network (HVTN) since 2004 and PI since 2011, this research has centered on the design and analysis of HIV vaccine efficacy trials, for which Dr. Gilbert has developed innovative statistical methods, and led or helped lead the analysis of the 6 HIV vaccine efficacy trials that have been conducted. In addition, Dr. Gilbert recently led the biostatistical design of the first efficacy trial of a monoclonal antibody for prevention of HIV infection. Dr. Gilbert was elected a Fellow of the American Statistical Association for his outstanding contributions in biostatistical research relevant to HIV vaccine efficacy trials by leading study design, analysis, and statistical methods development, especially in the areas of surrogate endpoint/correlates of protection evaluation and sieve analysis of pathogen sequences, conducted within the fields of semiparametric inference, survival analysis, and causal inference. Dr. Gilbert’s public health service includes chairing Data Safety Monitoring Boards and membership on advisory panels for groups conducting vaccine research, the NIH study section AIDS and Related Research Integrated Review Group (2004-2008), and the FDA’s Advisory Committee for Vaccines and Related Biological Products (VRBPAC, 2008-2012). For his whole career at the University of Washington Dr. Gilbert has been a very active advisor of biostatistics doctoral students on research topics emerging within vaccine efficacy trials.
Dr. Peter Gilbert is a biostatistician with many years of experience in the design and analysis of randomized clinical trials for preventive vaccines against HIV, malaria, dengue, and other pathogens; as well as for MTCT prevention and antiretroviral therapies. Through his work as co-PI of the statistical data management center (SDMC) for the HIV Vaccine Trials Network (HVTN) since 2004 and PI since 2011, this research has centered on the design and analysis of HIV vaccine efficacy trials, for which Dr. Gilbert has developed innovative statistical methods, and led or helped lead the analysis of the 6 HIV vaccine efficacy trials that have been conducted. In addition, Dr. Gilbert recently led the biostatistical design of the first efficacy trial of a monoclonal antibody for prevention of HIV infection. Dr. Gilbert was elected a Fellow of the American Statistical Association for his outstanding contributions in biostatistical research relevant to HIV vaccine efficacy trials by leading study design, analysis, and statistical methods development, especially in the areas of surrogate endpoint/correlates of protection evaluation and sieve analysis of pathogen sequences, conducted within the fields of semiparametric inference, survival analysis, and causal inference. Dr. Gilbert’s public health service includes chairing Data Safety Monitoring Boards and membership on advisory panels for groups conducting vaccine research, the NIH study section AIDS and Related Research Integrated Review Group (2004-2008), and the FDA’s Advisory Committee for Vaccines and Related Biological Products (VRBPAC, 2008-2012). For his whole career at the University of Washington Dr. Gilbert has been a very active advisor of biostatistics doctoral students on research topics emerging within vaccine efficacy trials.